Thera-SAbDab

OPICINUMAB

> Structural Summary

Therapeutic	Opicinumab
Target	LINGO1
Heavy Chain	EVQLLESGGGLVQPGGSLRLSCAASGFTFSAYEMKWVRQAPGKGLEWVSVIGPSGGFTFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCATEGDNDAFDIWGQGTTVTVSS
Light Chain	DIQMTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPMYTFGQGTKLEIK
100% seqID Fv Structure	4oqt [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4oqt [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-II
Estimated Status (June '19)	Active
Recorded Developmental Technology	Dyax Human Phage Display
INN Year Proposed	2015
INN Year Recommended	2106
Companies Involved	Biogen Idec, Dyax, Biogen
Conditions Approved	na
Conditions Active	Multiple sclerosis, Optic neuritis
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]